• Looking into the future
Our mission
Our mission

Bring native bispecific therapeutics to patients

Our antibody development roots go deep

CD47 targeting
CD47 targeting

Safe and selective blockade of CD47 on tumors

Safe and selective blockade of CD47 on tumors

CD28 targeting

Safe and selective CD28 co-stimulation

Safe and selective blockade of CD47 on tumors

Who we are
Who we are

Our antibody development roots go deep

Our antibody development roots go deep

Our technology
Our technology, natural bispecific antibodies

Multispecific yet natural

κλ bodies

Looking into the future
Looking into the future

Beyond bispecific antibodies

Beyond bispecific antibodies

previous arrow
next arrow
  • CD28 targeting
  • How it works

Looking into the future

Beyond bispecific antibodies

There is no doubt that bispecific antibodies represent a major step forward in the development of effective therapies to treat different diseases.

Complex indications as well as emerging treats such as infectious diseases require novel approaches to multi-targeting.

We are actively developing our antibody light chain approach to create bispecific antibody mixtures in a simple and reliable manner.

If you share our vision and want to work with us, please contact us.

First Patient dosed with NILK-2401 in Phase I clinical trial

First-in-human trial of NILK-2401, a CEACAM5xCD47 bispecific κλ body


Read more

LinkedIn